A paradigm shift in patent law?
Recent disputes between research-based pharma companies and generics have addressed the viability of use patents in PMNOC proceedings. Bill Richardson of McCarthy TÃ©trault LLP examines the cases and asks whether the Regulations need to be changed
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: